STAAR Surgical Gains Regulatory Approvals for Visian® ICL™ with CentraFLOW™ Technology in Korea and Argentina

 STAAR Surgical Gains Regulatory Approvals for Visian® ICL™ with CentraFLOW™
                      Technology in Korea and Argentina

~ CentraFLOW Technology Driving Greater Adoption of the ICL Procedure

~~Korea Currently Largest Market for ICL Technology

~~Argentina Market Key to Driving ICL Latin America Growth

~~ Nearly 20,000 Successful Implants of Visian ICLs with CentraFLOW Already
Performed in Europe~

PR Newswire

MONROVIA, Calif., June 17, 2013

MONROVIA, Calif., June 17, 2013 /PRNewswire/ -- STAAR Surgical Company
(NASDAQ: STAA), a leading developer, manufacturer and marketer of minimally
invasive ophthalmic products, today announced that it has received regulatory
approvals to market its Visian® Implantable Collamer® Lens (ICL™) with
CentraFLOW™ technology from the KFDA in Korea and the ANMAT in Argentina.

Don Todd, President of the Asia Pacific Region for STAAR Surgical said of the
approval in Korea, "The refractive procedure market in Korea is both
significant and fast growing, so this represents a very important milestone
for us. Woo Jeon VT, our Korean distributor, has successfully driven the ICL
market share in the country to over 12% of all refractive procedures. In
anticipation of this approval and product launch, we hired two STAAR employees
to work onsite at Woo Jeon's Korean offices. This new staff will be
instrumental in driving our market position even further following this
critical regulatory approval. We plan the official Launch Symposium in Korea
on July 27^th where approximately 100 surgeons will be trained on the new

Professor Tchah from Asan Medical Center, a leading refractive surgeon in
Seoul, Korea who will be the Moderator for the CentraFLOW Launch Symposium
said, "The introduction of the Visian ICL with CentraFLOW technology is a big
advancement to me and the myopic patients of Korea. Eliminating the need to
do a peripheral iridotomy procedure (PI) will make the entire experience very
simple and less stressful for the patients. For me as a surgeon, not having
to schedule and perform a PI procedure allows me to eliminate concerns about
any complications associated with the added procedure. We are looking forward
to introducing this enhancement in the Visian ICL procedure to our patients."

According to a Market Scope, 2013 Comprehensive Report on The Global
Refractive Surgery Market, Korea has 49 million people and approximately
138,000 refractive procedures were performed last year.

Commenting on the approval in Argentina, Hans Blickensdoerfer, STAAR
Surgical's President EMEA, Latin America, said "This is strategically an
important approval for our company as Latin America is historically an early
adopter of elective procedures, so this provides a critical gateway in our
ability to expand in this market. In 2012, the ICL had approximately a 7%
share of all refractive procedures in Argentina. The approval of the Visian
CentraFLOW technology means opening up the refractive market to further expand
penetration into a significantly wider approval range. We have seen this as
an important factor in our rapid growth of the Visian ICL in Europe since the
introduction of CentraFLOW. Moreover, it allows MED, our distributor in the
region to focus on positioning the ICL head to head with LASIK. We will be
working with them closely to ensure we maximize all our resources to expand
the opportunity there."

Dr. Roberto Zaldivar, a worldwide leading refractive surgeon from Argentina,
said, "I first implanted the Visian ICL with a hole in the center about 19
years ago in 30 eyes. I have followed these patients and the results have
been excellent. This is an incredible step forward as it saves time for the
surgeon and the patient and eliminates the potential for a pupillary block.
With the approval of CentraFLOW technology I will now be able to bring these
clinical benefits to my patients every day."

According to Market Scope's 2013 data, in Argentina, the population is about
42 million and approximately 22,000 refractive procedures were performed in

The CentraFLOW™ technology utilizes the KS-AquaPORT™, or KS-AP™, in the center
of the ICL optic, to optimize the flow of fluid within the eye. This
proprietary technology eliminates the need for the surgeon to perform a YAG
peripheral iridotomy procedure days before the ICL implant, thus eliminating
an additional procedure and office visit. This results in more comfort for
the patient and a more convenient, efficient ICL experience for both the
patient and the surgeon. The Visian ICL, which is currently the fastest
growing refractive technology, has demonstrated an even greater growth rate
with this enhancement. Nearly 20,000 successful implants of the Visian
CentraFLOW technology have been successfully performed in Europe.

These approvals expand the market opportunity for the Visian ICL as the range
of refractive errors treatable has significantly increased. These approvals on
the Visian ICL with CentraFLOW now goes from -0.5 diopter to -18.0 diopters on
the myopic range and +0.5 cylinder power to +6.0 for the Toric ICL models.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 25
years, designs, develops, manufactures and markets implantable lenses for the
eye and delivery systems therefor. All of these lenses are foldable, which
permits the surgeon to insert them through a small incision. STAAR's lens used
in refractive surgery as an alternative to LASIK is called an Implantable
Collamer® Lens or "ICL." A lens used to replace the natural lens after
cataract surgery is called an intraocular lens or "IOL." Over 350,000 Visian
ICLs have been implanted to date; to learn more about the ICL go to: STAAR has approximately 300 full time employees and
markets lenses in over 60 countries. Headquartered in Monrovia, CA, it
manufactures in the following locations: Nidau, Switzerland; Ichikawa City,
Japan; Aliso Viejo, CA; and Monrovia, CA. For more information, please visit
the Company's website at

Collamer® is the registered trademark for STAAR's proprietary biocompatible
collagen copolymer lens material.

Safe Harbor

All statements in this press release that are not statements of historical
fact are forward-looking statements, including any statements about the effect
of new product approvals on our business, any statements of belief and any
statements of assumptions underlying any of the foregoing.

These statements are based on expectations and assumptions as of the date of
this press release and are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those described in the
forward-looking statements. The risks and uncertainties include the following:
our need to compete against much larger and better financed companies in
selling refractive surgical procedures; our limited resources to promote new
products and the risk that product launches may be affected by unplanned
delays or be less successful than we anticipate; the effect of the global
recession on sales of products, especially products such as the ICL used in
non-reimbursed elective procedures, the entrenched position of laser-based
refractive surgical procedures in many markets, and the willingness of
surgeons and patients to adopt a new product and procedure. STAAR assumes no
obligation to update its forward-looking statements to reflect future events
or actual outcomes and does not intend to do so.

CONTACT: Investors                   Media
         EVC Group                   EVC Group
         Leigh Salvo, 415-568-9348   Christopher Gale
         Douglas Sherk, 415-568-9349 646-201-5431

SOURCE STAAR Surgical Company

Press spacebar to pause and continue. Press esc to stop.